HMGB1 and metabolic dysfunction-associated steatohepatitis: Mechanistic studies reveal that the bioactivity of YJ3A1 may involve the inhibition of HMGB1 expression and release, thereby suppressing the HMGB1/TLR4/NF-κB and Akt signaling pathways to mitigate the progression of NASH [117].